A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

NCT05113862 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus
SARS-CoV-2 Infection
COVID-19

Interventions

BIOLOGICAL: LD Vehicle-GNP
BIOLOGICAL: LD PepGNP-Covid19
BIOLOGICAL: HD Vehicle-GNP
BIOLOGICAL: HD PepGNP-Covid19

Sponsor

Gylden Pharma Ltd

Collaborators

[object Object]
[object Object]